1.Advances in the diagnosis and treatment of mantle cell lymphoma
Chinese Journal of Clinical Oncology 2016;43(19):835-839
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin's lymphomas (NHLs). MCL comprises distinct subtypes with different pathological characteristics and clinical features. However, MCL remains incurable by intensified first-line regimens con-taining cytarabine and involving consolidation with high-dose therapy and autologous stem cell transplantation. Recently discovered somatic mutations and aberrant intracellular signaling pathways have been demonstrated to play an essential role in the pathogenesis of MCL. The related novel therapeutics, such as Btk inhibitors, PI3K inhibitors, and immune modulators, have exhibited promising ther-apeutic effects on untreated or even relapsed/refractory MCL. The development of an efficient combination therapy is urgently need-ed to improve the survival of MCL patients in the future.
2.Diagnosis and treatment of mucosa-associated lymphoid tissue lymphoma
Lingyan PING ; Jun ZHU ; Yuntao ZHANG
Journal of Leukemia & Lymphoma 2009;18(3):185-187
To describe the epidemiology, etiology, pathological features, clinical manifestation,diagnosis and management, and the role of surgery in mucosa-assoeiated lymphoid tissue (MALT) lymphoma.The relationship between the pathogenesis of gastric MALT lymphoma and helicobacter pylori infection, and its therapeutic principles and follow up study were specially stressed.
3.Effects of buzhong yiqi and rehabilitation training on post-stroke fatigue
Ling FENG ; Zhenfen SIMA ; Lingyan HE ; Yuefeng WU ; Yibei NIU ; Renxiang PING ; Hong FAN
Chinese Journal of Physical Medicine and Rehabilitation 2014;36(6):421-424
Objective To observe the effects of a decoction of buzhong yiqi in conjunction with rehabilitation training in relieving post-stroke fatigue.Methods A group of 115 stroke patients was enrolled and randomly divided into a simple rehabilitation group and a combination therapy group.Both groups received conventional rehabilitation treatment and appropriate treatment of any primary diseases.In addition,those in the combination therapy group were given a decoction of buzhong yiqi twice daily for a total of 4 weeks.EMG signals,subjective evaluations of fatigue severity,active rehabilitation exercise duration,motor function and ability in the activities of daily living (ADL) were assessed before treatment and after 4 weeks of treatment.The slope of the surface electromyogram's mean power frequency (KMPF) and median frequency (KMF) were used to quantify fatigue.Subjective fatigue severity was estimated using a fatigue severity scale (FSS).The active rehabilitation exercise lasted,on average,90 minutes daily.The Fugl-Meyer assessment (FMA) was used to evaluate motor function and the modified Barthel index (MBI) ADL ability.Results There were no statistically significant differences between the groups before treatment.After 4 weeks of treatment all the outcomes in both groups had improved (except the FSS scores of the simple rehabilitation group).The KMPF,KMF,FSS,exercise duration,FMA scores and MBI scores in the combination therapy group were all significantly better than those in the simple rehabilitation group.Conclusion Taking buzhong yiqi can significantly improve the clinical effects of conventional rehabilitation training on post-stroke fatigue.It helps relieve fatigue,improve active participation in rehabilitation exercise,and also improve motor function and ADL ability.
4.Clinical Analysis of 13 Cases of Burkitt Lymphoma and Burkitt-like Lymphoma
Ningjing LIN ; Wen ZHENG ; Yuntao ZHANG ; Xiaopei WANG ; Yuqin SONG ; Yan XIE ; Meifeng TU ; Lingyan PING ; Jun ZHU
Chinese Journal of Clinical Oncology 2010;37(1):5-8
Objective:To summarize the clinical characteristics of Burkitt lymphoma(BL)and Burkitt-like lymphoma(BLL)and the effect of treatment on 13 cases,and to explore the treatment-related complications and optimal treatment.Methods:Clinical data of 13 BL and BLL patients treated between August 1996 and October 2008 in our hospital were retrospectively analyzed.All of these patients received chemotherapy as the first-line treatment.The efficacy and adverse reactions were evaluated.Results:Of the 13 patients,there were 12 males and 1 female,with a median age of 15 years(ranging from 11 to 62).There were 3 stage Ⅰ cases,2 stage Ⅱ cases,2 stage Ⅲ cases,and 6 stage Ⅳ cases.The advanced stage(stage Ⅲ and Ⅳ)patients accounted for 61.5%(8 cases).CNS was involved in 4 cases and bone marrow was involved in 2 cases at diagnosis.The commonly involved sites included superficial lymph nodes(61.5%),abdominal organs(53.8%),and celiac and retro-pentoneal lymph nodes(38.5%).B symptoms were observed in 7 patients(53.8%).Serum lactate dehydrogenase level was elevated in 8 of 10 cases,while serum udc acid level was elevated in 1 of 10 cases.Eleven patients were diagnosed as BL and 2 patients were diagnosed as BLL.Of the 13 patients,11(84.6%) achieved complete remission(CR)or CR/unconfirmed(CRu),and 1 patient(7.7%) got partial remission(PR).Dudng the follow-up of 8 months(ranging from 5 to 35),6 patients were still alive.The 1-year overall survival,progression-free survival and disease-free survival were 56.98%,32.31% and 39.77%,respectively.Nine patients(69.2%)developed grade Ⅲ or Ⅳ myelosuppression.Conclusion:Intensive short-course chemotherapy is the optimal first-line treatment for BL and BLL.
5.Efficacy and safety of modified baseline BEACOPP regimen in the treatment of advanced Hodgkin's lymphoma
Ningjing LIN ; Yuntao ZHANG ; Wen ZHENG ; Xiaopei WANG ; Yuqin SONG ; Meifeng TU ; Lingyan PING ; Zhitao YING ; Jun ZHU
Tumor 2010;(1):42-47
Objective:To investigate the safety and efficacy of a modified baseline BEACOPP regimen(bleomycin+etoposide+adriamycin+cyclophosphamide+vincristine+ procarbazine hydrochloride+ prednisone) in the treatment of advanced Hodgkin 's lymphoma (HL). Methods:From March 2006 to September 2008, 22 previously untreated patients with stages Ⅱ(bulky), Ⅲ and Ⅳ HL were treated with a modified baseline BEACOPP regimen. Each patient was scheduled to receive 6 to 8 cycles of BEACOPP with consolidation radiotherapy to bulky (≥5 cm) or residual disease.Results:There were 11 males and 11 females with a median age of 28 years (15 to 61 years old). Twelve patients (54.5%) had nodular sclerosis HL, and 10(45.5%) had mixed cellularity HL. There were 4 patients in stageⅡ, 7 in stage Ⅲ and 11 in stage Ⅳ. Sixteen patients (72.7%) achieved a complete remission (CR) and 5 patients (22.7%) had partial remission (PR). The total effective rate (CR+PR) was 95.5%. Among all kinds of clinical factors International Prognostic Score (IPS) had significant effect on CR rate (P=0.011). The 1-, 2- and 3-year total survival rates were the same (95.5%); the 1-, 2- and 3-year progression-free survival (PFS) rates were 72.7%, 53.1% and 53.1%, respectively;the 1-, 2- and 3-year disease-free survival rates were 85.9%, 76.4% and 76.4%,respectively. Univariate analysis showed that the gender, IPS and whether achieving CR had significant effects on PFS (P<0.05). The main toxic effects were bone marrow depression and liver injury. Three patients (13.6%) had grade Ⅲ drug-induced lung injury. No treatment-related death was observed.Conclusion:The modified baseline BEACOPP regimen was effective and safe for treatment of newly diagnosed patients with advanced HL.
6.Analysis of clinical features and prognosis of 98 patients with mantle cell lymphoma
Lingyan PING ; Wen ZHENG ; Xiaopei WANG ; Yan XIE ; Ningjing LING ; Meifeng TU ; Zhitao YING ; Weiping LIU ; Chen ZHANG ; Lijuan DENG ; Yuqin SONG ; Jun ZHU
Chinese Journal of Clinical Oncology 2014;(19):1234-1238
Objective:To study the clinical features, therapeutic effects, survival time, and prognosis of patents with mantle cell lymphoma (MCL). Methods:Clinical data of 98 MCL patients admitted from January 2005 to December 2013 were retrospectively an-alyzed. Results:The median age was 61 years old, and the male-to-female ratio was 2.9∶1. Among these cases, 85 (86.8%) were in Ann Arbor stageⅢ-Ⅳ, 46 (46.9%) had bone marrow involvement, 25 (25.5%) had digestive tract involvement, and 53 chose R-CHOP as first-line treatment. The expected 3-year overall survival (OS) of these patients was only 61.4%. A total of 14 cases were treated with R-CHOP followed by ASCT. The expected 5-year OS was 92.3%, and the OS of the ASCT group was significantly higher than that of the R-CHOP group (75.5 months vs. 43.6 months, P=0.039). Elevated ESR,>60 years old, increased LDH level, B symptoms, and Ki-67≥25% were poor prognostic factors. Conclusion: Most patients with MCL were elder adults with bone marrow involvement. R-CHOP followed by ASCT had better clinical efficacy than conventional chemotherapy in the treatment of MCL.
7.Preimplantation genetic diagnosis of infantile malignant osteopetrosis in a Chinese family.
Ping YUAN ; Yanhong ZENG ; Lingyan ZHENG ; Jia DENG ; Jing WANG ; Yanwen XU ; Canquan ZHOU
Chinese Journal of Medical Genetics 2015;32(3):307-311
OBJECTIVETo explore the application of preimplantation genetic diagnosis (PGD) for infantile malignant osteopetrosis (IMO).
METHODSFor a family affected with IMO, PGD was provided using combined parental mutation detection and haplotype constructions with microsatellite markers spanning the TCIRG1 gene. Prenatal diagnosis was performed on the chorionic villus and amniocentesis samples by direct sequencing.
RESULTSPrenatal diagnosis showed that the fetus by the third pregnancy has carried the parental mutations [c.242delC (p.Pro81Argfs*85) and c.1114C>T (p.Gln372*)], and the pregnancy was terminated. PGD was subsequently performed through mutations detection and haplotype analyses following whole genome amplification (WGA) of each of 13 cells. The results showed that 6 of the 13 embryos were unaffected, 3 were carriers and 4 were affected. Well developed unaffected/carrier embryos were selected and transferred into the uterus. A single pregnancy was confirmed. Subsequently pre- and post-natal diagnoses have confirmed development of a healthy child.
CONCLUSIONThe study demonstrated the advantage of PGD over prenatal diagnosis when natural pregnancies have repeatedly produced IMO children/fetuses.
Adult ; Base Sequence ; Female ; Fertilization in Vitro ; Fetus ; Genetic Carrier Screening ; Humans ; Infant ; Male ; Microsatellite Repeats ; Molecular Sequence Data ; Osteopetrosis ; diagnosis ; embryology ; genetics ; prevention & control ; Pedigree ; Point Mutation ; Pregnancy ; Preimplantation Diagnosis ; Vacuolar Proton-Translocating ATPases ; genetics
8.Status quo survey of nutrition work ability in primary medical institutions of Chongqing City
Ping FENG ; Jiahui CHEN ; Cheng LONG ; Ying ZHANG ; Lingyan YUAN ; Shuquan LUO ; Jingrong CHEN
Chongqing Medicine 2024;53(13):2028-2032
Objective To understand the status quo of nutrition working ability in primary medical and health institutions of Chongqing City.Methods Three primary medical institutions were randomly extracted from each of 39 districts and counties of Chongqing City,and Primary Nutrition Service Capacity Survey Form and Nutrition Work Capacity Survey System were adopted to conduct the questionnaire survey.Then the sur-vey results were analyzed.Results A total of 117 primary medical institutions were surveyed,in which 86 in-stitutions(73.50%)undertook the nutritional work.The number of engaging the nutrition full-time work in the units was 0(0,0).Among the nutritional staff,the age in 164 persons was 30-<40 years old,accounting for 48.38%,180 persons(53.10%)had the primary title,232 persons(68.44%)had the bachelor degree,287 persons(84.66%)had the medical related background,but only 2 persons had the nutritional related profes-sional background.There were 57(48.72%),75(64.10%),77(65.81%)primary medical institutions in carry-ing out the nutrition and health management of pregnant women,children aged 0-6 years old and elderly peo-ple,34 institutions(29.10%)in carrying out nutritional monitoring,and 17 institutions(14.50%)had the clinical nutrition work ability.Compared with the villages and towns,the proportion of urban area primary medical institutions in carrying out the blood routine items in children aged 0-6 years old,hemoglobin,blood routine and urine routine items in elderly people was higher,the number of published popular science works on nutrition was more,and the differences were statistically significant(P<0.05).Conclusion The nutrition work system of primary medi-cal institutions in Chongqing City is temporarily imperfect,the specialized persons still lack and the nutritional health service level needs to be further strengthened.
9.Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma.
Weiping LIU ; Xiaopei WANG ; Chen ZHANG ; Yan XIE ; Ningjing LIN ; Meifeng TU ; Lingyan PING ; Zhitao YING ; Lijuan DENG ; Huiying HUANG ; Meng WU ; Yingli SUN ; Tingting DU ; Xin LENG ; Ning DING ; Wen ZHENG ; Yuqin SONG ; Jun ZHU
Chinese Journal of Hematology 2016;37(4):269-272
OBJECTIVETo compare the prognostic value of different models in patients with early-stage diffuse large B-cell lymphoma (DLBCL).
METHODSEarly-stage DLBCL patients diagnosed from January 2000 to December 2012 were analyzed retrospectively. All patients received with at least 2 cycles of immunochemotherapy R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with or without radiotherapy. The prognostic value of international prognostic index (IPI) , revised IPI (R-IPI) and enhanced IPI (NCCN-IPI) was compared.
RESULTSNinety-seven cases of early-stage DLBCL were included in the study. The median age was 58 years (15-88 years) with a median follow-up of 34.7 months (range 7.3-77.4 months). The expected 5-year overall survival (OS) for entire group was 82%. There was no patient in the high risk group according to IPI or NCCN-IPI. According to IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 95%, 38% and 60%, respectively. According to R-IPI, the 5-year OS in the very good, good, and poor risk groups were 93%, 75% and 60%, respectively. According to NCCN-IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 92%, 85% and 29%, respectively.
CONCLUSIONNCCN-IPI would be of an ideal prognostic model for early-stage DLBCL patients.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Combined Chemotherapy Protocols ; Cyclophosphamide ; Doxorubicin ; Humans ; Immunotherapy ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; Middle Aged ; Prednisone ; Prognosis ; Retrospective Studies ; Rituximab ; Vincristine ; Young Adult
10.Case Study of Compound Traditional Chinese Medicine Globalization
He SUN ; Zhixin GUO ; Lingyan LI ; Shunnan ZHANG ; Yi HE ; Xiaohui MA ; Genbei WANG ; Ping WANG ; Liu YANG
World Science and Technology-Modernization of Traditional Chinese Medicine 2017;19(6):914-923
Compound Traditional Chinese Medicine (CTCM) applying for FDA approval as botanical drug is a systemic and innovative work.Compound Danshen Dripping Pill (T89) is the first CTCM completed FDA global multi-center Phase Ⅲ clinical trial,which has become a benchmark for TCM globalization.Extensive experiences have been accumulated through the 20 years' research and development.Tasly fully considered the characteristics of CTCM while complying with FDA regulations during the entire application process.In which,product indication was clearly defined and agreed,clinical trial protocol was scientifically and innovatively designed with gold standard,phase Ⅱ study was well completed,SPA for phase Ⅲ study was obtained,and eventually the global multi-center phase Ⅲ study was successfully completed.In order to better support T89's application,Tasly conducted series of additional studies and introduced many innovations,such as drug-drug interaction study for TCM,finger printing study for CTCM,quality consistency study,biological assay study and etc.Globalization of T89 is not only a product creating history,but also a process for Tasly and the US FDA working together to continuously innovate and create history in innovating modern TCM standards,improving industrial chain GMP system for botanical drugs,making technical breakthroughs,exploring regulatory pathways and increasing product value.It represents the national power and historical progress in medicine.